PRGN-3005 UltraCAR-T cells
Phase 1Biologic
PRGN-3005 UltraCAR-T cells is one of 15 biologic programs targeting Primary Peritoneal Cancer. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Primary Peritoneal Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Avastin
RochePhase 3
Paraplatin
AAvyxa
Phase 3
Tecentriq
RochePhase 3
Femara
NovartisPhase 3
Keytruda
Merck & Co.Phase 2
Erivedge
RochePhase 2
Glucophage
EMD SeronoPhase 2
Empaveli
Apellis PharmaceuticalsPhase 2
Fludara
SanofiPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRGN-3005 UltraCAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- PPrecigen, Inc